Fundamentally improving the current cost levels, leading to global impact.
The unique combination of molecular biology, robotics, NGS and data interpretation provides market-leading accuracy.
Enabling massive scalability in terms of number of targets and samples.
Geno1® is a proprietary kit-based pre-sequencing technology that combines molecular biology, robotics, next-generation DNA sequencing (NGS) and data interpretation.
Geno1® addresses the key shortcomings of NGS-based solutions through its minimalistic but powerful design, leading to substantially lower test costs, higher test accuracy and faster turn-around-time. Geno1® is also massively scalable technology in terms of number of samples and targets. It unlocks the future of distributed kits.
Geno1® unlocks the use of NGS in an unprecedented way and democratises the precision diagnostics.
Geno1® is based on unique, patented Bridge Capture target enrichment workflow that maximizes the power of NGS platforms. It can be adapted to any next-generation sequencing platform.
The laboratory design of Geno1® has been guided by the principle of minimalism: reduce all processing steps to minimum and make them as simple as possible. Through these design choices, Geno1® provides a lightweight but powerful molecular counting platform which scales to any number of relevant targets within any number of patient samples.
We offer Geno1® for out-licensing and are continuously looking for new long-term partnerships both within oncology and other verticals.